EP3793548A4 - Composés pour le traitement du cancer du pancréas - Google Patents

Composés pour le traitement du cancer du pancréas Download PDF

Info

Publication number
EP3793548A4
EP3793548A4 EP19802725.2A EP19802725A EP3793548A4 EP 3793548 A4 EP3793548 A4 EP 3793548A4 EP 19802725 A EP19802725 A EP 19802725A EP 3793548 A4 EP3793548 A4 EP 3793548A4
Authority
EP
European Patent Office
Prior art keywords
compounds
treatment
pancreatic cancer
pancreatic
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP19802725.2A
Other languages
German (de)
English (en)
Other versions
EP3793548A1 (fr
Inventor
Wei Li
Duane D Miller
Subhash Chauhan
Vivek Kumar Kashyap
Wang QINGHUI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Tennessee Research Foundation
Original Assignee
University of Tennessee Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Tennessee Research Foundation filed Critical University of Tennessee Research Foundation
Publication of EP3793548A1 publication Critical patent/EP3793548A1/fr
Publication of EP3793548A4 publication Critical patent/EP3793548A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Furan Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
EP19802725.2A 2018-05-15 2019-05-15 Composés pour le traitement du cancer du pancréas Withdrawn EP3793548A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862671833P 2018-05-15 2018-05-15
PCT/US2019/032476 WO2019222392A1 (fr) 2018-05-15 2019-05-15 Composés pour le traitement du cancer du pancréas

Publications (2)

Publication Number Publication Date
EP3793548A1 EP3793548A1 (fr) 2021-03-24
EP3793548A4 true EP3793548A4 (fr) 2022-03-09

Family

ID=68541005

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19802725.2A Withdrawn EP3793548A4 (fr) 2018-05-15 2019-05-15 Composés pour le traitement du cancer du pancréas

Country Status (9)

Country Link
US (1) US20190374512A1 (fr)
EP (1) EP3793548A4 (fr)
JP (1) JP2021523915A (fr)
KR (1) KR20210021982A (fr)
CN (1) CN112437664A (fr)
AU (1) AU2019270091A1 (fr)
CA (1) CA3099922A1 (fr)
MX (1) MX2020012292A (fr)
WO (1) WO2019222392A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20230413A1 (es) * 2020-04-03 2023-03-07 Veru Inc Metodos de tratamiento del coronavirus
CA3215936A1 (fr) * 2021-04-05 2022-10-13 Veru Inc. Methodes de traitement d'une inflammation
CN119212696A (zh) * 2022-04-28 2024-12-27 维鲁公司 [2-(1h-吲哚-3-基)-1h-咪唑-4-基](3,4,5-三甲氧基)甲酮和其盐的多晶型物

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011109059A1 (fr) * 2010-03-01 2011-09-09 Gtx, Inc. Composés destinés au traitement du cancer
WO2012027481A1 (fr) * 2010-08-24 2012-03-01 Gtx, Inc. Composés utilisés dans le traitement du cancer
US20120071524A1 (en) * 2010-03-01 2012-03-22 Yan Lu Compounds for treatment of cancer
US20140213623A1 (en) * 2008-06-16 2014-07-31 Gtx, Inc. Compounds for treatment of cancer
US20160015688A1 (en) * 2013-03-05 2016-01-21 University Of Tennessee Research Foundation Compounds for treatment of cancer

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9447049B2 (en) * 2010-03-01 2016-09-20 University Of Tennessee Research Foundation Compounds for treatment of cancer
MX2010014066A (es) * 2008-06-16 2011-06-01 Univ Tennessee Res Foundation Compuestos para el tratamiento del cancer.

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140213623A1 (en) * 2008-06-16 2014-07-31 Gtx, Inc. Compounds for treatment of cancer
WO2011109059A1 (fr) * 2010-03-01 2011-09-09 Gtx, Inc. Composés destinés au traitement du cancer
US20120071524A1 (en) * 2010-03-01 2012-03-22 Yan Lu Compounds for treatment of cancer
WO2012027481A1 (fr) * 2010-08-24 2012-03-01 Gtx, Inc. Composés utilisés dans le traitement du cancer
US20160015688A1 (en) * 2013-03-05 2016-01-21 University Of Tennessee Research Foundation Compounds for treatment of cancer

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2019222392A1 *

Also Published As

Publication number Publication date
AU2019270091A1 (en) 2020-12-24
WO2019222392A1 (fr) 2019-11-21
EP3793548A1 (fr) 2021-03-24
KR20210021982A (ko) 2021-03-02
CN112437664A (zh) 2021-03-02
JP2021523915A (ja) 2021-09-09
CA3099922A1 (fr) 2019-11-21
US20190374512A1 (en) 2019-12-12
MX2020012292A (es) 2021-03-29

Similar Documents

Publication Publication Date Title
MA49144A (fr) Polythérapies pour le traitement du cancer
EP3781564C0 (fr) Dérivés de pyridazine pour le traitement du cancer
EP3935050A4 (fr) Composés hétérocycliques pour traitement médical
MA43746A (fr) Dérivés de 2-cyanoisoindoline pour le traitement du cancer
EP3431105A4 (fr) Composition médicinale pour le traitement du cancer
EP3728271A4 (fr) Composés macrocycliques pour le traitement de maladie
MA50409A (fr) Polythérapies pour le traitement du cancer
MA48637A (fr) Polythérapies pour le traitement du cancer
EP3397963A4 (fr) Inhibition de mapk p38 pour le traitement du cancer
EP3452060A4 (fr) Polythérapie pour le traitement du cancer
MA51139A (fr) Dérivés de 1-(pipéridinocarbonylméthyl)-2-oxopipérazine pour le traitement du cancer
EP3400010A4 (fr) Combinaisons anti-her2 pour le traitement des tumeurs
EP3630196A4 (fr) Polythérapies pour le traitement de cancers
EP3317274A4 (fr) Utilisation de composés de chloroquine et de clémizole pour le traitement d'états pathologiques inflammatoires et cancéreux
EP3947460A4 (fr) Agents multispécifiques pour le traitement du cancer
EP3541417A4 (fr) Immunothérapies d'association pour le traitement du cancer
EP3490561A4 (fr) Combinaisons pour le traitement du cancer
EP3478284A4 (fr) Composés et compositions pour le traitement du cancer
EP3471722A4 (fr) Composés et méthodes pour la prévention et/ou le traitement du cancer
MA51738A (fr) Composés pour le traitement de la douleur
EP3416645A4 (fr) Composés pour le traitement du paludisme
EP3793544A4 (fr) Compositions bifonctionnelles pour le traitement du cancer
EP3503887A4 (fr) Combinaisons pour le traitement du cancer
EP3411073A4 (fr) Combinaisons pour le traitement du cancer
EP3990458A4 (fr) Composés pour le traitement du cancer

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20201215

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Free format text: PREVIOUS MAIN CLASS: A61K0031416400

Ipc: A61K0031416800

A4 Supplementary search report drawn up and despatched

Effective date: 20220208

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 35/00 20060101ALI20220202BHEP

Ipc: A61K 31/427 20060101ALI20220202BHEP

Ipc: A61K 31/4178 20060101ALI20220202BHEP

Ipc: A61K 31/4168 20060101AFI20220202BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20220908

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230525